EF Hutton Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics (NASDAQ:TRVI) and maintained a price target of $21.
October 21, 2024 | 4:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics and maintained a price target of $21, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $21 price target by EF Hutton suggests a positive outlook for Trevi Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100